Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study

Abstract

IntroductionMalignant pleural mesothelioma (MPM) is an asbestos-related cancer, which is difficult to diagnose. Thoracoscopy is frequently required but is not widely available. An accurate, non-invasive diagnostic biomarker would allow early specialist referral, limit diagnostic delays and maximise clinical trial access. Current markers offer insufficient sensitivity and are not routinely used. The SOMAmer proteomic classifier and fibulin-3 have recently demonstrated sensitivity and specificity exceeding 90% in retrospective studies. DIAPHRAGM (Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma) is a suitably powered, multicentre, prospective observational study designed to determine whether these markers provide clinically useful diagnostic and prognostic information.Methods and analysisSerum and plasma (for SOMAscan and fibulin-3, respectively) will be collected at presentation, prior to pleural biopsy/pleurodesis, from 83 to 120 patients with MPM, at least 480 patients with non-MPM pleural disease and 109 asbestos-exposed controls. Final numbers of MPM/non-MPM cases will depend on the incidence of MPM in the study population (estimated at 13–20%). Identical sampling and storage protocols will be used in 22 recruiting centres and histological confirmation sought in all cases. Markers will be measured using the SOMAscan proteomic assay (SomaLogic) and a commercially available fibulin-3 ELISA (USCN Life Science). The SE in the estimated sensitivity and specificity will be <5% for each marker and their performance will be compared with serum mesothelin. Blood levels will be compared with paired pleural fluid levels and MPM tumour volume (using MRI) in a nested substudy. The prognostic value of each marker will be assessed and a large bioresource created.Ethics and disseminationThe study has been approved by the West of Scotland Research Ethics Committee (Ref: 13/WS/0240). A Trial Management Group meets on a monthly basis. Results will be published in peer-reviewed journals, presented at international meetings and disseminated to patient groups.Trial registration numberISRCTN10079972, Pre-results.

Biomarkers in the diagnosis of pleural diseases: a 2018 update

“… 69 Currently, a prospective, multicenter study, named DIAPHRAGM (Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma), is trying to determine whether a multiplexed proteomic platform will provide clinically useful serum markers of mesothelioma. 70 …”

Progress and challenges in Mesothelioma: From bench to bedside

“…However, a large meta-analysis reported poor sensitivity (32%) at 95% specificity [26], so negative results are of little value, particularly in non-epithelioid disease. The other markers require prospective validation, which is currently ongoing [30]. The most important future role for circulating markers may be as early indicators of treatment response, given the cost of emerging therapies.…”

Aptamer-Based Proteomics Identifies Mortality-Associated Serum Biomarkers in Dialysis-Dependent AKI Patients

“…SOMAscan has been applied to studies on several types of medical conditions to identify proteins and molecular mechanisms involved in disease progression. 14 , 15 , 16 , 17 , 18 , 19 To better understand the pathogenesis associated with high mortality in AKI-D patients, we performed SOMAscan proteomic profiles on serum samples collected from 207 participants in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network (ATN) study.…”